Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 10
Submit an article Journal homepage
285
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy

Jiajia LiuDivision of Adult and Pediatric Hematology, University of Toronto, Toronto, Canada; ORCID Iconhttp://orcid.org/0000-0002-5471-6392
ORCID Icon,
Douglas StewartTom Baker Cancer Centre, Calgary, Canada; ORCID Iconhttp://orcid.org/0000-0001-5531-0960
ORCID Icon,
Amelie FontaineCross Cancer Institute, Edmonton, Canada;
,
Anthea PetersCross Cancer Institute, Edmonton, Canada; ORCID Iconhttp://orcid.org/0000-0002-2570-339X
ORCID Icon,
Isabelle FleuryMaisonneuve-Rosemont Hospital, Montreal, Canada;
,
Luigina MollicaMaisonneuve-Rosemont Hospital, Montreal, Canada;
,
Anca PricaPrincess Margaret Cancer Centre, Toronto, Canada;
,
Rena BucksteinOdette Cancer Centre – Sunnybrook Health Sciences Centre, Toronto, Canada;
,
Laurie SehnCentre for Lymphoid Cancer, British Columbia Cancer, Vancouver, Canada;
,
Aixiang JiangCentre for Lymphoid Cancer, British Columbia Cancer, Vancouver, Canada; ;Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
,
John KuruvillaPrincess Margaret Cancer Centre, Toronto, Canada;
&
Diego VillaCentre for Lymphoid Cancer, British Columbia Cancer, Vancouver, Canada; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-4625-3009
ORCID Icon show all
Pages 2492-2496 | Received 14 Feb 2020, Accepted 13 May 2020, Published online: 10 Jun 2020

References

  • Bachy E, Seymour JF, Feugier P, et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA Study. J Clin Oncol. 2019;37(31):2815–2824.
  • Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210.
  • Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018;379(10):934–947.
  • Cheah CY, Seymour JF. When to treat patients with relapsed follicular lymphoma. Expert Rev Hematol. 2017;10(3):187–191.
  • NCCN. B-cell lymphomas (version 4.2019) 2019. [updated June 18, 2019;September 2, 2019]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
  • Casulo C, Friedberg JW, Ahn KW, et al. Autologous transplantation in follicular lymphoma with early therapy failure: a national lymphocare study and center for international blood and marrow transplant research analysis. Biol Blood Marrow Transplant. 2018;24(6):1163–1171.
  • Jurinovic V, Metzner B, Pfreundschuh M, et al. Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German low grade lymphoma study group. Biol Blood Marrow Transplant. 2018;24(6):1172–1179.
  • Oh DH, Li H, Duan Q, et al. Quantifying benefit of autologous transplantation for relapsed follicular lymphoma patients via instrumental variable analysis. Biol Blood Marrow Transplant. 2016;22(5):941–948.
  • Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26(32):5165–5169.
  • Link BK, Day BM, Zhou X, et al. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol. 2019;184(4):660–663.
  • Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516–2522.
  • Freeman CL, Kridel R, Moccia AA, et al. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood. 2019;134(9):761–764.
  • Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016;17(1):57–66.
  • Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17(8):1081–1093.
  • Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188–1199.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.